Floatz logo

Veledimex

Glioblastoma

Alaunos TherapeuticsSmall moleculePhase 2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
65/ 100

Competitive context

354 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

Veledimex is also rated in:

breast cancerDormant
CCC
Indicative ·
49 / 100
View asset →
melanomaDormant
CC
Indicative ·
44 / 100
View asset →
brain neoplasmDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →